Clinical Trial Update: This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. [Phase 3]

View source ↗

Summary

Open-label extension of a double-blind, randomized Phase 3 core study in primary progressive multiple sclerosis; the trial was terminated and results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Progressive Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2017-06-14